DOCSLIB.ORG

Medicines Used Across Wirral Health Economy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines Used Across Wirral Health Economy Medicines used across Wirral Health Economy Below is a list of medicines that are approved for use on Wirral. Some medicines may only be prescribed in hospital, others may be prescribed by your GP. The list is updated every time a new medicine is approved for use in Wirral. Some medicines have been recommended by the National Institute for Health and Care Excellence (NICE). The middle column of the table below indicates recommendations made by NICE — eg, TA234 means that the medicine was reviewed in NICE technology appraisal number 234. Some of the medicines we use are recommended by specialists working from the Walton Centre NHS Foundation Trust or from the Cheshire and Wirral Partnership NHS Foundation Trust. These medicines are included in our formulary — however; the prescriber retains responsibility for the appropriate use of these medicines. These formularies are obtainable here: http://www.panmerseyapc.nhs.uk/formulary/documents/04- 0800_antiepileptic_drugs.pdf http://www.panmerseyapc.nhs.uk/formulary/documents/04-09- 00_parkinsonism.pdf http://www.cwp.nhs.uk/pages/629-pharmacy-and-medicines-information Subject to NICE Drug Name recommendation Abatacept TA195, TA280 Acamprosate Acarbose Accu-Chek Inform II® AccuSol® 35 Potassium 4mmol/L Acetazolamide Acetylcysteine Acencoumarol Acetic acid 5% solution Acetone Acitretin Aciclovir Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Aclinidium Actilite® Activated Charcoal Activon® - see Honey dressing Activon Tulle® - see Honey dressing Actrapid® (Soluble Insulin) TA195, TA199, TA187, TA146, Adalimumab TA143, TA130, TA329 Adapalene (Differin®) 0.1% cream/gel Adcal D3 / Forte Addiphos® Additrace Adefovir dipivoxil TA96 Adenosine Adrenaline Aflibercept TA294, TA305 Alcohol Alendronate TA160, TA161 Alfacalcidol Alfentanil Alfuzosin Algivon® Alemtuzumab Alimemazine (Trimeprazine) Aliskiren Alitretinoin TA177 Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Allantoin (Alphosyl HC®) Allopurinol Almotriptan Alogliptin Alprostadil Alteplase TA264, TA122, TA52 Aluminium acetate Aluminum acetate ear drops 13% (unlicensed) Aluminium hydroxide (Alu-Caps®) Alverine citrate Amantadine Ametop® see Tetracaine gel Amikacin Aminophylline Amiodarone Amisulpride Amitriptyline Amlodipine Amorolfine Amoxicillin Amphotericin Amphotericin - Liposomal (AmBisome®) Ampicillin Amsacrine Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Anagrelide Anakinra Anastrazole TA112 Antacid and Oxetacaine Anti-D immunoglobulin TA156 Anti-human thymocyte immunoglobuin Antipeol® see zinc oxide Anusol® Aprepitant Apixaban TA275, TA245 Apomorphine (APO-go®) Aquacel® Aquacel Ag® Aquacel ribbon® Aquaform® Aqueous cream (SLS free) — ZeroAQS® Aquagel Arachis oil Argatroban Aripiprazole Artificial Saliva (Saliveze® Oral Spray Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Artificial tears Ascorbic acid Aspirin Atazanavir (Reyataz®) Atenolol Atomoxetine TA98 Atorvastatin TA94 Atosiban Atracurium Atrauman® Atrauman Ag® Atropine Atripla® (Efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) Auranofin Aveeno® Azacitadine TA218 Azathioprine Azithromycin Aztreonam Bacillus Calmette Guerin bladder installation Baclofen Bactroban®see Mupirocin Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Balsalazide Balneum Plus® BCG vaccine (intradermal) Beclometasone Beclometasone / formeterol (Fostair®) Bendamustine TA216 Bendroflumethiazide Benzathine Penicillin Benzocaine gel (Ultracare®) Benzoyl peroxide (Duac Once Daily®) Benzydamine Benzylpenicillin Beta-carotene Betadine® Betahistine Betamethasone Betamethasone 0.1% and Neomycin Sulfate 0.5% ointment Bettamouse Bevacizumab Biatain Super® Bicalutamide Biobag larvae dressings Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 BioFOAM® Biotene Oral Balance gel® Bisacodyl Bisoprolol Bleomycin Boceprevir TA253 Bortezomib TA228, TA311 Bosentan Botulinum toxin Type A & B Breast Milk Fortifier (Nutriprem BMF®) Budesonide Bumetanide Bupivacaine Bupivacaine with adrenaline Buprenorphine TA114 Bupropion Buserelin Busulfan (Busulphan) C1-esterase inhibitor Cabergoline Caffeine citrate Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Calceos® Calcichew D3 /Forte® Calcipotriol Calcitonin Calcitriol Calcium acetate (PhosLo®, Phosex®) Calcium carbonate (Calcichew®) Calcium chloride Calcium folinate Calcium gluconate/gel Calcium resonium (Calcium polystyrene sulphonate) Calfovit D3® Calogen® Canagliflozin TA315 Candesartan Capsaicin Captopril Carbamazepine Carbimazole Carbocisteine Carboflex® Carboplatin Carboprost (Hemobate®) Carmellose (Celluvisc®) Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Carmustine Carob bean gum Carvedilol Caspofungin Cavilon® Cefaclor Cefadroxil Cefalexin (Cephalexin) Cefradine (Cephradine) Ceftaroline Cefotaxime Ceftazidime Cefotaxime Ceftriaxone Cefuroxime Celecoxib Cerazette® Certolizumab TA186 Cetirizine Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Cetraben® Cetrimide (aqueous) 0.15%, chlorhexidine gluconate 0.015% in water (pre-sterilised sachet). (Tisept®) Cetrorelix Charcoal see Activated Charcoal Chloral hydrate Chlorambucil Chloramphenicol Chlordiazepoxide Chlorhexidine gluconate 0.05% antispetic solution (Unisept® pre-sterilised sachet) Chlorhexidine gluconate dressing (Biopatch®) Chlorhexidine gluconate 4% (Hydrex® Hibiscrub®) Chlorhexidine gluconate 0.5% in ethanol antiseptic solution (Hydrex® solution) Chlorhexidine gluconate 0.5% in 70% isopropyl alcohol antispetic solution with emollients (HiBi Liquid®) Chlorhexidine gluconate mouthwash 0.2% Chlorhexidine gluconate 2% in 70% isopropyl alcohol (ChloraPrep® 3ml applicator) Chlorhexidine gluconate 2% in 70% isopropyl alcohol (Clinell Blue® skin wipes) Chlorhexidine 2% in IPA 70% Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Chlorphenamine Chlorpromazine Choline salicylate gel Chondroitin sulphate (Uracyst®) Chorionic gonadotrophin Ciclosporin Cidofovir Cilastatin Cilest® Cilostazol Cinacalcet TA117 Ciprofloxacin Cisplatin Citalopram Cladribine Clarithromycin Clenil Modulite® (Beclomethasone) Clindamycin Clinisorb® Clobazam Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Clobetasol propionate (Dermovate®) Clobetasone butyrate (Eumovate®) (Trimovate®) Clofarabine Clomifene Clomipramine Clonazepam Clonidine Clopidogrel TA210 Clotrimazole Clozapine (Clozaril®) Coal tar (Exorex®) Co-amoxiclav Co-codamol Co-cyprindiol Co-danthramer Codeine Colchicine Colecalciferol Colestyramine Colistimethate Sodium TA276 Colistin Co-beneldopa (Benserazide,levodopa) (Madopar®) Co-careldopa (Carbidopa/Levodopa) (Caramet®, Sinemet®) Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Colomycin (Colistimethate sodium or colistin sulfomethate sodium) Combivir® (Zidovudine 300mg, lamivudine 150mg) Comfeel Plus dressing (contour, transparent & ulcer) ® Conjugated oestrogens Conotrane® Cream ( Benzalkonium chloride 0.1% w/w, dimeticone 22% w/w) Co-trimoxazole Creon® Crisantaspase (Asparaginase) Cyclizine Cyclopentolate (Minims®) Cyclophosphamide Cyclo-progynova Cyproheptadine Cytarabine Dabigatran TA249, TA157, TA327 Dacarbazine Dactinomycin Dalivit® Danaparoid Dantrolone Dapagliflozin TA288 Dapsone Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Daptomycin Darbepoetin alfa (Aranesp®) TA323 Darunavir (Prezista®) Dasatinib Daunorubicin Deferasirox Deferiprone Degarelix Demeclocycline TA265, TA204 Denosumab Dermamist® (White soft paraffin) Dermol® Dermol 500® Desferrioxamine Desmopressin Dexamethasone Dexamethaxone intravitreal implant (Ozurdex®) TA229 Dexamfetamine TA98 Dextrosol® Dialyvit (renal) Diamorphine Dianeal PD4 2500 ml 1.36% APD Fluid Yellow Wirral Medicines Formulary Author: Medicines Management Team Approved by: Wirral Drug and Therapeutics Panel Last updated: June 2015 Version 10 Dianeal PD4 5000 ml 1.36% APD Fluid Yellow Dianeal PD4 2500 ml 2.27% APD Fluid Green Dianeal PD4 5000 ml 2.27% APD Fluid Green Dianeal PD4 2500 ml 3.86% APD Fluid Orange Dianeal PD4 5000 ml 3.86% APD Fluid Orange Dianeal PD4 1500 ml 1.36%CAPD Fluid Yellow Dianeal PD4 2000 ml 1.36% CAPD Fluid Yellow Dianeal PD4 2500 ml 1.36% CAPD Fluid Yellow Dianeal PD4 1500 ml 2.27% CAPD Fluid Green Dianeal PD4 2000 ml 2.27% CAPD Fluid Green Dianeal PD4 2500 ml 2.27%CAPD Fluid Green Dianeal PD4 2000 ml 3.86% CAPD Fluid Orange Diazepam Diazoxide Diclofenac Dicobalt edetate Dicycloverine hydrochloride Digoxin Digoxin Antibody (Digibind®
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Ep 1931310 B1
    (19) & (11) EP 1 931 310 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 9/06 (2006.01) 06.06.2012 Bulletin 2012/23 A61K 9/70 (2006.01) A61K 47/32 (2006.01) A61K 47/24 (2006.01) A61K 47/10 (2006.01) (21) Application number: 06779420.6 (86) International application number: (22) Date of filing: 14.09.2006 PCT/GB2006/003408 (87) International publication number: WO 2007/031753 (22.03.2007 Gazette 2007/12) (54) Monophasic film-forming composition for topical administration Monophasische filmbildende Zusammensetzung zum topischen Auftrag Composition monophase formant un film pour l’administration à voie topique (84) Designated Contracting States: • JONES, Stuart, Allen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR London SE3 0XA (GB) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Lord, Hilton David Marks & Clerk LLP (30) Priority: 14.09.2005 GB 0518769 90 Long Acre London (43) Date of publication of application: WC2E 9RA (GB) 18.06.2008 Bulletin 2008/25 (56) References cited: (73) Proprietor: Medpharm Limited WO-A2-01/43722 US-A- 4 752 466 Charlbury, US-A- 4 863 721 US-A1- 2004 184 994 Oxfordshire OX7 3RR (GB) US-A1- 2004 213 744 (72) Inventors: • BROWN, Marc, Barry Hertfordshire WD19 4QQ (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Quick Practice Guides Index with Few Exceptions, the Quick Practice Guides in PCF Are Restricted to a Maximum of 2 Pages in Order to Facilitate Everyday Use
    PCF4_Cover_MAY.qxp 8/18/11 2:57 PM Page 2 Quick Practice Guides Index With few exceptions, the Quick Practice Guides in PCF are restricted to a maximum of 2 pages in order to facilitate everyday use. Before using them, it is important to study the associated text in order to fully understand their rationale. Page Chapter 1: Gastro-intestinal system Management of death rattle (noisy respiratory secretions) 8 Opioid-induced constipation 38 Bowel management in paraplegia and tetraplegia 40 Chapter 4: Central nervous system Depression 187 Psychostimulants in depressed patients with a short prognosis 209 Management of nausea and vomiting 225 Chapter 5: Analgesics Management of procedure-related pain 379 Use of transdermal buprenorphine 388 Use of transdermal fentanyl patches 398 Use of methadone for cancer pain 422 Chapter 6: Infections Cellulitis in lymphoedema 459 Chapter 16 Management of death rattle (noisy respiratory secretions) repeat 637 Chapter 20 Setting up a McKinley T34 syringe pump for CSCI 673 Setting up a Graseby MS16A or MS26 syringe driver for CSCI 676 Chapter 22 Administration of drugs by enteral feeding tube 700 PCF4 PALLIATIVE CARE FORMULARY This first print-run of PCF4 has been made possible, in part, by Help the Hospices, the leading charity supporting hospice care throughout the United Kingdom. www.helpthehospices.org.uk Published by palliativedrugs.com Ltd. Palliativedrugs.com Ltd Hayward House Study Centre Nottingham University Hospitals NHS Trust, City Campus Nottingham NG5 1PB United Kingdom www.palliativedrugs.com # palliativedrugs.com Ltd 2011 The moral rights of the editors have been asserted. PCF3 2007, reprinted 2008, 2009 PCF2 2002, reprinted 2003 PCF1 1998 All rights reserved.
    [Show full text]
  • Anaesthetic Antacids: a Review of Its Pharmacological Properties and Therapeutic Efficacy
    International Journal of Research in Medical Sciences Parakh RK et al. Int J Res Med Sci. 2018 Feb;6(2):383-393 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180005 Review Article Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy Rajendra Kumar Parakh*, Neelakanth S. Patil Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India Received: 13 December 2017 Accepted: 27 December 2017 *Correspondence: Dr. Rajendra Kumar Parakh, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids.
    [Show full text]
  • Local Anaesthesia (LA): an Overview
    68 Review Article Local Anaesthesia (LA): An Overview Mayure Vijay Kumar*, V. Sravanthi Department of pharmacology, Maheshwara College of Pharmacy, Hyderabad, Andhra Pradesh, India. *[email protected] ABSTRACT The anaesthetic agents are the drugs which causes anaesthesia-reversible loss sensation. It deals with the property of relieving the pain without eliminating sensation. These drugs are generally administered to facilitate surgery. It can be described by two main classes. General anaesthetic, which causes a reversible loss of consciousness, and local anaesthetics, which causes a reversible loss of sensation for a limited region of the body while maintaining consciousness. Here I explain about the Local anaesthetics agents that prevent transmission of nerve impulses without causing unconsciousness. They act by binding to fast sodium channels from within in an open state. BACKGROUND: The purpose of this Review article is to summarize the Local anaesthetics agents, general mechanism, structures, therapeutic uses, adverse effects and also explains their properties. Keywords: Local Anaesthesia, relieving pain, nerve impulses INTRODUCTION (General) cocaine’s pharmacologic actions and adverse Cocaine is a naturally occurring compound effects were elucidated during this time. In the indigenous to the Andes Mountains, West 1880s, Koller introduced cocaine to the field of Indies, and Java. It was the first anaesthetic to ophthalmology, and Hall introduced it to be discovered and is the only naturally dentistry. Halsted was the first to report the use occurring Local anaesthetic; all others are of cocaine for nerve blocks in the US in 1885 synthetically derived. Cocaine was introduced in and also became addicted to the drug through to Europe in the 1800s following its isolation self-experimentation.
    [Show full text]
  • Veterinary Medicines
    VETERINARY MEDICINES A compact collection of information on Veterinary drugs/medicines in practice Prepared By : Dr. ANWAR ALAM KHAN eMail and FaceBook : [email protected] Sep-2013 CHAPTERS 1 Gastrointestinal & Hepatobiliary System 2 Infection and Infestations 3 Cardiovascular System 4 Nervous System 5 Respiratory System 6 Allergic Disorders 7 Urinary System 8 Genital System 9 Eye & Ear 10 Topical Applications 11 Nutrition and Metabolism 12 Exclusive Formulations 13 Surgical 14 Livestock Biologicals 15 Diagnostics 16 Ayurvedics Page 2 1...Gastrointestinal & Hepatobiliary System GASTROINTESTINAL & HEPATOBILIARY SYSTEM Antemetics PROMETHAZINE Phenothiazines. Anti-Histaminic, H1 receptar antagonist Phenergan NPIL Promethazine inj 2ml Dog 1-2ml--IM or Nausea, Vomition Slow-IV syp 60 ml tab 10mg Dog 25mg DOMPERIDONE Dopamine receptar Antagonist Domstal Torrent Domperidone drops 5 ml Dog Puppies, 2--3 Nausea, Vomiting. drops susp 30 ml Dog 5-10 ml orally tab 5,10,20 mg Dog 1-2 tab before meals Vomistop Cipla Domperidone drops 30ml Dog 5-10 ml tab 10mg Dog 1-2 tab METACLOPRAMIDE Perinorm IPCA Metaclopramide inj 2ml, 10ml Dog 0.05~2ml--IV Nausia, Vomition liq 30 ml Dog 5-10 ml tab 5mg, 10mg, Dog 5-10 mg DT-5mg ONDANESTRON Belongs to the class of serotonin (5HT3) antagonists Emeset Cipla Ondanestron inj 2ml, 4ml Dog 2-4 ml Nausea, Vomiting syp 30 ml Dog 5-10 ml orally tab 4mg, 8mg Dog 4mg, 8mg Ondem Alkem Ondanestron inj 2ml, 4ml Dog 1--2 ml, IM Nausea, Vomiting (2mg/ml) susp 30 ml Dog Page 3 1...Gastrointestinal & Hepatobiliary System Antacids,
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]